U.S., Aug. 22 -- ClinicalTrials.gov registry received information related to the study (NCT07779629) titled 'Efficacy & Safety of Fluoroquinolone-Based Brucellosis Regimens (BRUCE)' on Aug. 14.
Brief Summary: Brucellosis is a globally distributed zoonosis with persistent clinical management challenges. The World Health Organization(WHO)-recommended doxycycline-rifampin (DOX-RIF) dual regimen may drive rifampin-associated antimicrobial resistance across all brucellosis-endemic regions. Patients with osteoarticular brucellosis require long-term intravenous ceftriaxone triple therapy, which is linked to poor treatment adherence due to repeated hospital visits and outpatient care demands. Fluoroquinolones (levofloxacin [LVX], moxifloxacin [MXF...